Astion Pharma A/S – Product Pipeline Review – H2 2011

Document Sample
Astion Pharma A/S – Product Pipeline Review – H2 2011 Powered By Docstoc
					Astion Pharma A/S – Product Pipeline Review




      Astion Pharma A/S – Product Pipeline Review – H2
                           2011

                                                                                          Reference Code: GMDHC02027CDB
                                                                                                 Publication Date: DEC 2011




Astion Pharma A/S – Product Pipeline Review – H2 2011                                     GMDHC02027CDB / Published DEC 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                               Page(1)
Astion Pharma A/S – Product Pipeline Review




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 4
    List of Figures ................................................................................................................................................................................ 4
Astion Pharma A/S Snapshot ............................................................................................................................................................. 5
    Astion Pharma A/S Overview ........................................................................................................................................................ 5
    Key Information ............................................................................................................................................................................. 5
    Key Facts....................................................................................................................................................................................... 5
Astion Pharma A/S – Research and Development Overview ............................................................................................................. 6
    Key Therapeutic Areas .................................................................................................................................................................. 6
Astion Pharma A/S – Pipeline Review ................................................................................................................................................ 8
    Pipeline Products by Stage of Development ................................................................................................................................. 8
    Pipeline Products – Monotherapy ................................................................................................................................................. 9
Astion Pharma A/S – Pipeline Products Glance ............................................................................................................................... 10
    Astion Pharma A/S – Late Stage Pipeline ................................................................................................................................... 10
        Phase III Products/Combination Treatment Modalities ........................................................................................................... 10
    Astion Pharma A/S Clinical Stage Pipeline Products................................................................................................................... 11
        Phase II Products/Combination Treatment Modalities ............................................................................................................ 11
        Phase I Products/Combination Treatment Modalities ............................................................................................................. 12
    Astion Pharma A/S – Early Stage Pipeline Products ................................................................................................................... 13
        Pre-Clinical Products/Combination Treatment Modalities ....................................................................................................... 13
Astion Pharma A/S – Drug Profiles .................................................................................................................................................. 14
    ASF-1057 .................................................................................................................................................................................... 14
        Product Description................................................................................................................................................................. 14
        Mechanism of Action ............................................................................................................................................................... 14
        R&D Progress ......................................................................................................................................................................... 14
    ASF-1085 .................................................................................................................................................................................... 15
        Product Description................................................................................................................................................................. 15
        Mechanism of Action ............................................................................................................................................................... 15
        R&D Progress ......................................................................................................................................................................... 15
    ASF-1096 .................................................................................................................................................................................... 16
        Product Description................................................................................................................................................................. 16
        Mechanism of Action ............................................................................................................................................................... 16
        R&D Progress ......................................................................................................................................................................... 16
    ASF-1097 .................................................................................................................................................................................... 17
        Product Description................................................................................................................................................................. 17
        Mechanism of Action ............................................................................................................................................................... 17
        R&D Progress ......................................................................................................................................................................... 17
    ASF-1102 .................................................................................................................................................................................... 18
        Product Description................................................................................................................................................................. 18
        Mechanism of Action ............................................................................................................................................................... 18
        R&D Progress .......................................................................
				
DOCUMENT INFO
Description: Astion Pharma A/S – Product Pipeline Review – H2 2011 Summary Global Market Direct’s pharmaceuticals report, “Astion Pharma A/S - Product Pipeline Review - H2 2011” provides data on the Astion Pharma A/S’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Astion Pharma A/S’s corporate website, SEC filings, investor presentations and featured press releases, both from Astion Pharma A/S and industry-specific third party sources, put together by Global Markets Direct’s team. Scope - Astion Pharma A/S - Brief Astion Pharma A/S overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Astion Pharma A/S human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Astion Pharma A/S with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Astion Pharma A/S’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products. Reasons to buy - Evaluate Astion Pharma A/S’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Astion Pharma A/S in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Astion Pharma A/S’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportuniti
BUY THIS DOCUMENT NOW PRICE: $500 100% MONEY BACK GUARANTEED
PARTNER GlobalMarketsDirect
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. Global Markets Direct has a broad range of coverage over key market segments. It has a global scope, covering a broad range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries